1.	Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: UMCN-AKF 07.02, EudraCTnr 2007-003347-73, NCT00588835
2.	Phase III Randomized Study of Different Combinations of Granisetron Hydrochloride, Dexamethasone, Prochlorperazine, Aprepitant, and Palonosetron Hydrochloride in Preventing Delayed Nausea in Patients Undergoing Chemotherapy for Chemotherapy-Naive Breast Cancer Phase: Phase III Type: Supportive care Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: URCC-04-02, URCC 0402, URCC-U1105, U1105, NCT00475085
3.	Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-Dose Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EmNa (2001-004956-38), EudraCT-No: 2004-004956-38, NCT00571168
4.	Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 15 and over Sponsor: Other Protocol IDs: QL05-37, NCT00572572
5.	Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IGAR-02-2009, 2008-001237-95, NCT00869973
6.	Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin Phase: Phase III Type: Supportive care Status: Approved-not yet active Age: 18 to 80 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2009-09-119, NCT01012336
7.	Phase II Pilot Study of Palonosetron Hydrochloride, Aprepitant, and Low-Dose Dexamethasone in Preventing Nausea and Vomiting in Patients Undergoing High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma or Lymphoma Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: KUMC-10862, 10862, MGI-KUMC-10862, NCT00631930
8.	Ondansetron Versus Aprepitant Plus Ondansetron for Emesis Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0615, NCT00954941
9.	Pilot Study of Aprepitant for Preventing Nausea and Vomiting in Patients With Pancreatic Cancer Receiving Gemcitabine Hydrochloride, Fluorouracil or Capecitabine, and Radiotherapy Phase: No phase specified Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CCCWFU-02205, CCCWFU-EMEND, MERCK-CCCWFU-02205, NCT00398164
10.	Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-1033, NCT00651755
11.	Randomized Study of the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UNC-LCCC-0514, UNC-05-2917, UNC-GCRC-2411-ORC, NCT00719173